It's famous that genetic variability in AMP metabolism could possibly be clinically relevant because of highly polymorphic character of CYP2D6. In idea, CYP2D6 lousy metabolizers may very well be predicted to involve smaller sized doses of AMP and/or be extra prone to adverse effects from routine clinical doses, when CYP2D6 ultra-speedy metabolizer